Abstract
Abacavir therapy is associated with significant drug hypersensitivity in approximately 8% of recipients, with retrospective studies indicating a strong genetic association with the HLA-B*5701 allele. In this prospective study, involving 260 abacavir-naive individuals (7.7% of whom were positive for HLA-B*5701), we confirm the usefulness of genetic risk stratification, with no cases of abacavir hypersensitivity among 148 HLA-B*5701-negative recipients.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Anti-HIV Agents / adverse effects*
-
Australia
-
Cohort Studies
-
Dideoxynucleosides / adverse effects*
-
Drug Hypersensitivity / epidemiology
-
Drug Hypersensitivity / genetics*
-
Drug Hypersensitivity / prevention & control
-
Female
-
Genetic Testing
-
HIV Infections / drug therapy*
-
HLA-B Antigens / genetics*
-
Humans
-
Incidence
-
Male
-
Middle Aged
Substances
-
Anti-HIV Agents
-
Dideoxynucleosides
-
HLA-B Antigens
-
HLA-B*57:01 antigen
-
abacavir